Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | BRS3 | P32247 | 2/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8861086 | 0.83 | FOLH1 (0.47) | MAPTMEN1KMT2AALOX5APFEN1 | |
| SCHEMBL13701698 | 0.83 | CHRNB2 (0.59) | MAPTMEN1KMT2AALOX5APFEN1 | |
| SCHEMBL7303110 | 0.82 | MAPT (0.54) | MAPTMEN1KMT2AALOX5APFEN1 | |
| SCHEMBL16125429 | 0.78 | BRS3 (0.41) | MEN1KMT2AALDH1A1SLC6A3BRS3 | |
| SCHEMBL29390423 | 0.78 | SLC6A3 (0.68) | KMT2ATSHRSLC6A3BRS3LTB4R2 | |
| SCHEMBL562 | 0.78 | SLC6A3 (0.68) | KMT2ATSHRSLC6A3BRS3LTB4R2 | |
| SCHEMBL283 | 0.77 | SLC6A3 (0.48) | MEN1KMT2AALDH1A1SLC6A3BRS3 | |
| SCHEMBL365731 | 0.77 | LTB4R2 (0.57) | BRS3LTB4R2 | |
| SCHEMBL29502712 | 0.77 | LTB4R2 (0.57) | BRS3LTB4R2 | |
| SCHEMBL8670912 | 0.77 | SLC6A3 (0.66) | KMT2ASLC6A3BRS3LTB4R2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298763-B1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-03-25 | — | — | EP | disclosed |
| US-8735598-B2 | Method for producing 1-biphenylmethylimidazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| US-20110092713-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2298763-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| EP-0503785-B1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| EP-0545912-B1 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-04-25 | — | — | EP | disclosed |
| US-5646171-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-07-08 | — | — | US | disclosed |
| US-5616599-A | HYPOTENSIVE AGENTS FOR CARDIOVASCULAR DISORDER | SANKYO COMPANY, LIMITED (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092713-A1 | METHOD FOR PRODUCING 1-BIPHENYLMETHYLIMIDAZOLE COMPOUND | AGTR1, AGTR2, AOC3 | MAPT 4452/4885MEN1 3299/4885KMT2A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.